Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T

(MedPage Today) -- A phase Ib/II study demonstrated that mosunetuzumab (Lunsumio) plus polatuzumab vedotin (Polivy) induced durable responses in patients with relapsed or refractory large B-cell lymphoma (LBCL), including patients who relapsed...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news